medigraphic.com

2015, Number 2

<< Back Next >>

Revista Cubana de Angiología y Cirugía Vascular 2015; 16 (2)

Behavior of glycosylated hemoglobin type 2 in diabetics with diabetic macroangiopathy in the lower members

Triana MME, Zapata VJA, Ameneiro PS, Pol MN, Llanes BJA

Language: Spanish
References: 25
Page: 154-163
PDF size: 147.45 Kb.


ABSTRACT

Introduction: glycosylated hemoglobin is used to evaluate the level of glycemic control. It has been reported that its decrease by 2 % reduces the occurrence or progression of micro or macrovascular complications.
Objective: to determine the behavior of glycosylated hemoglobin in type 2 diabetes patients with macroangiopathy in lower limbs.
Method: study of one hundred type 2 diabetic patients with/without diabetic macroangiopathy in their lower limbs; 36 were males and 64 females averagely aged 61.8 years (44-74 years). The level of hemoglobin glycosylation was quantitated as well as the reference value was estimated. The kind of association of this indicator with several risk factors and with the type of diabetic macroangiopathy was also established and described.
Results: the reference value of 8.6 % of the glycosylated hemoglobin was chosen because it was the cutoff point with the highest sensitivity (73.7 %), specificity (83.7 %) and probability odds (4.52) values. Poor glycemic control was confirmed in 48.3 % of patients, mainly affected by occluded macroangiopathy (44.8 %). In decompensated patients, dyslipidemia was the predominant risk factor (58.3 %) along with the combination of smoking and blood hypertension (35.3 %).
Conclusions: the type 2 diabetic patients with occluded diabetic macroangiopathy of the lower limbs showed very high glycosylated hemoglobin values indicative of poor metabolic control.


REFERENCES

  1. American Diabetes Association (ADA). Diagnosis and classification of diabetes mellitus. Position Statement Diabetes Care. 2012;35(suppl 1):s64-71. doi: 10.2337/dc12-s064.

  2. Organización Mundial de la Salud. Las enfermedades no transmisibles, un problema de salud de primer orden para el siglo XXI. Estadísticas Sanitarias Mundiales 2012. Ginebra: OMS; 2012 [citado 30 oct 2013]:1-178. Disponible en: http://www.who.int/healthinfo/ES_WHS2012_Full.pdf

  3. Bornfeldt KE. 2013 Russell Ross Memorial Lecture in Vascular Biology: Cellular and Molecular Mechanisms of Diabetes Mellitus-Accelerated Atherosclerosis. Arterioscler Thromb Vasc Biol. 2014 [cited 2014 Abr 17];34:705-14. doi: 10.1161/ATVBAHA.113.301928. Available from: http://atvb.ahajournals.org/content/34/4/705.full.pdf+html

  4. American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care. 2012;35:11-63.

  5. Triana ME. La hiperglucemia y sus efectos tóxicos. Un concepto patogénico para la micro- y macroangiopatía [actualización]. Rev Cubana Angiol Cir Vasc 2001 [citado 15 Sept 2013];2(2):131-42. Disponible en: http://bvs.sld.cu/revistas/ang/vol2_2_01/ang102201.htm

  6. Nathan DM. The pathophysiology of diabetic complications: how much does the glucose hypothesis explain? Ann Intern Med. 1996;124(1-2):36-9.

  7. The Diabetes Control and Complications Trial Data Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes. 1995;44:968-83.

  8. The Diabetes Control and Complications Trial (DCCT) Research Group. Effect of intensive diabetes management on macrovascular events and risk factors in the diabetes control and complications trial. Am J Cardiol. 1995;75:894-903.

  9. The United Kingdon Prospective Diabetes Study Data Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type2 diabetes. (UKPDS 33). Lancet. 1998;352:837-53.

  10. Catapano AL, Reiner Z, de Backer G, Graham I, Taskinen MR, Wiklund O, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis. 2011 [cited 2014 Abr 16];217(Suppl 1):S1-44. doi: 10.1016/ j. atherosclerosis.2011.06.012. Available from: http://www.sciencedirect.com/science/article/pii/S0021915011004898

  11. Messner B, Bernhard D. ATVB in Focus: Tobacco related cardiovascular diseases in the 21st Century smoking and cardiovascular disease mechanisms of endothelial dysfunction and early atherogenesis. Arteriosclerot Thromb Vasc Biol. 2014;34:509- 15. doi: 10.1161/?ATVBAHA.113.300156

  12. James PA, Oparil S, Carter BL, et al. Evidence based-guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014 [cited 2014 Abr 16];152:1-14. doi:10.1001/jama.2013.284427. Available from: http://www.jama.jamanetwork.com/journal.aspx

  13. Kerr M. Degree of obesity correlates with mortality risk. JAMA. 2006;296:79-86.

  14. Llanes Barrios JA, Álvarez Duarte HT, Toledo Fernández AM, Fernández Montequín J, Torres Herrera OF, Chirino Carreño N, et al. Manual para la prevención, diagnóstico y tratamiento del pie diabético. Rev Cubana Angiol Cir Vasc. 2009 [citado 15 Sept 2013];10(1):42-96. Disponible en: http://bvs.sld.cu/revistas/ang/vol10_01_11/ang08111.htm

  15. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014 [cited 2014 Nov 30];129:S1-S45. doi:10.1161/01.cir.0000437738.63853.7a. Available from: http://circ.ahajournals.org/content/129/25_suppl_2/S1.full.pdf+html

  16. Bronas UG, Salisbury D. Clinical strategies for managing dyslipidaemias. Am J Lifestyle Med. 2013 [cited 2014 Jan 5];20(10):1-16. doi: 10.1177/1559827613507534. Available from: http://www.ajl.sagepub.com/content/early/2013/10/20/1559827613507534.full.pdf+html

  17. Go AS, Bauman MA, Coleman King SM, Fonarow GC, Lawrence W, Williams KA, et al. An effective approach to high blood pressure control: A science advisory from the American Heart Association, the American College of Cardiology, and the Centers for disease control and prevention. Hypertension. 2014 [cited 2014 Abr 17];63:878-85. doi: 10.1161/HYP.0000000000000003. Available from: http://hyper.ahajournals.org/content/suppl/2013/11/12/HYP.0000000000000003.DC1.html

  18. Examination Committee of criteria for obesity disease in Japan. Japan Society for the study of obesity. New criteria for obesity disease in Japan. Cir J. 2002;66:987-92.

  19. Aldama A, Vega ME, Ley J, Fernández J, Lima B, Alvarez H, et al. Haemodinamic classification of diabetic macroangiopathy. J Vasc Invest. 1998;4(4):171-4.

  20. Trivielle LA, Ranne THM, Lay HT. Haemoglobin components in patients with diabetes mellitus. N Engl J Med. 1971;284:353-7.

  21. Trask LE, Abbott D, Lee HK. Low hemoglobin A1c: good diabetic control? Clin Chem. 2012;58:648-9.

  22. Selvin E, Wattanakit K, Steffes MW, Coresh J, Sharrett AR. HbA1c and peripheral arterial disease in diabetes: the Atherosclerosis Risk in Communities study. Diabetes Care. 2006;29(4):877-82.

  23. Aronow WS. Hemoglobin-A1c Linked to Peripheral Arterial Disease Severity in Diabetics. Am J Cardiol. 2007;99:1468-9.

  24. Paraskevas KI, Bessias N, Papas TT, Gekas CD, Andrikopoulos V, Mikhailidis DP. Do different vascular risk factors affect all arteries equally? Angiology. 2008;59(4):397-401.

  25. 25.Gudbjörnsdottir S, Eeg-Olofsson K, Cederholm J, Zethelius B, Eliasson B, Nilsson PM. Risk factor control in patients with Type 2 diabetes and coronary heart disease: findings from the Swedish National Diabetes Register (NDR). Diabet Med. 2009;26(1):53-60.




2020     |     www.medigraphic.com